Benign Prostate Hyperplasia. Benign neoplasm of prostate
Conditions
Interventions
Intervention 1: Intervention group: Lycopene and FruHis supplement group (1 capsule daily containing 25 mg lycopene and 10 mg FruHis). Intervention 2: Intervention group: Supplementation group of FruH
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with BPH, whose disease is diagnosed by an urologist, range in age from 50 to 75 years. a serum PSA level between 4-10 ng / ml and have a negative DRE test. Negative DRE test.
Exclusion criteria
Exclusion criteria: Use of Finasteride or other anti-androgen drugs for the last 6 months. Prostate cancer and other malignancies such as skin, myeloma and bladder cancers. Chronic diseases such as severe liver disease and renal failure. Bladder and kidney stones. Lycopene supplementation in the last 6 months Any allergies and sensitivities to tomatoes or tomato products
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum PSA Levels. Timepoint: at the baseline and end of intervention. Method of measurement: Immuno Chemi Luminance.;Serum free-PSA Levels. Timepoint: at the baseline and end of intervention. Method of measurement: Immuno Chemi Luminance.;Serum IGF-1 Levels. Timepoint: at the baseline and end of intervention. Method of measurement: ELISA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of illness. Timepoint: at the baseline and end of intervention. Method of measurement: International Prostate Symptom Score(IPSS) questionnaire.;Quality of life. Timepoint: at the baseline and end of intervention. Method of measurement: International Prostate Symptom Score(IPSS) questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAlireza Sadeghi
Tehran University of Medical Sciences
Outcome results
None listed